Wyeth slams Merck Sharp & Dohme’s ‘baseless’ invalidity claim in vaccine trial

Allens 2018-12-04 3:44 pm By Miklos Bolza | Sydney

Please login to bookmark

Pharmaceutical giant Wyeth has accused Merck Sharp & Dohme of a “baseless” patent invalidity case, saying on the second day of trial over the world’s best selling vaccine that the development of its patented Prevnar 13 pneumococcal shot was anything but obvious, as its rival contends.

Subscribe to Lawyerly to access this article.

Already a subscriber?
Lost your password?

For information on rights and reprints, contact subscriptions@lawyerly.com.au